Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718127 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL11198199 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL3363495 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6889028 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL5697577 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL8540328 | 0.99 | GSK3B (0.49) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6882003 | 0.89 | GSK3B (0.38) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL5697584 | 0.86 | GSK3B (0.49) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6882333 | 0.86 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6887317 | 0.86 | GSK3B (0.49) | GSK3BADKTSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | GSK3B 314/4885ADK 296/4885TSHR 4510/4885 |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | NTPCR, PNP, TYMP | GSK3B 132/4885ADK 48/4885TSHR 2417/4885 |
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | SAMHD1, TYMP, NUDT1 | GSK3B 967/4885ADK 482/4885TSHR 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.